205 results on '"Bourget, Philippe"'
Search Results
2. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial
3. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
4. Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children
5. L’arrêt de la ranitidine IV ou son passage per os sont-ils possibles chez l’enfant en nutrition parentérale au long cours ?
6. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial
7. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas
8. Plasma and intraprostatic concentrations of ertapenem following preoperative single dose administration: a single-centre prospective experience and clinical implications—the ERTAPRO study
9. State of the art and future directions of pancreatic ductal adenocarcinoma therapy
10. Design and Development of a User-Friendly Motorized Apparatus for the Filling of Portable Infusion Pumps by Hospital and Homecare Health Workers
11. Liquid chromatography–tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis
12. Supplement to: Gene thereapy in a patient with sickle cell disease.
13. Gene Therapy in a Patient with Sickle Cell Disease: Brief Report
14. Modèle de coopération médico-pharmaceutique comme contributeur au succès du conditionnement de la greffe allogénique de cellules souches hématopoïétiques chez l’adulte : un regard croisé sur nos organisations
15. Microbiological and Physicochemical Stability of Oxycodone Hydrochloride Solutions for Patient-Controlled Delivery Systems
16. Routine application of Raman spectroscopy in the quality control of hospital compounded ganciclovir
17. The contribution of Raman spectroscopy to the analytical quality control of cytotoxic drugs in a hospital environment: Eliminating the exposure risks for staff members and their work environment
18. Comparison of Raman spectroscopy vs. high performance liquid chromatography for quality control of complex therapeutic objects: Model of elastomeric portable pumps filled with a fluorouracil solution
19. Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy
20. Microbiological and Physicochemical Stability of Fentanyl and Sufentanil Solutions for Patient-Controlled Delivery Systems
21. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning
22. Liquid chromatography–mass spectrometry assay for quantitation of ifosfamide and its N-deschloroethylated metabolites in rat microsomal medium
23. Models for Placental Transfer Studies of Drugs
24. Stellate Ganglion Blockade: Pharmacokinetics of Lidocaine With and Without Epinephrine
25. Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: Application to camptothecin derivatives
26. Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products
27. High-performance thin-layer chromatography with a derivatization procedure, a suitable method for the identification and the quantitation of busulfan in various pharmaceutical products
28. Contribution of high-performance thin-layer chromatography to a pharmaceutical quality assurance programme in a hospital chemotherapy manufacturing unit
29. Results from the Completed Hgb-205 Trial of Lentiglobin for β-Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy
30. Intracerebral administration of rAAV2/5hNAGLU vector in children with MPS IIIB: results at 30 months of a phase I/II trial
31. Abstract B57: Effects of MEK inhibition alone or in combination with PI3K-mTOR pathway inhibitors in pancreatic ductal adenocarcinoma in vitro and on an innovative ex vivo fresh tumor tissue culture model
32. Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene Therapy: Sustained Clinical Benefit in Severe Hemoglobinopathies
33. Midostaurin in Advanced Systemic Mastocytosis
34. 279. Clinical Outcomes of Gene Therapy with BB305 Lentiviral Vector for Sickle Cell Disease and β-Thalassemia
35. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-GlobinGene
36. Reiterated Therapeutic Drug Monitoring (TDM) Dosing to Significantly Improve the Control of Exposure to IV Busulfan in Infants and Older Children Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)
37. Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector
38. Contribution and limits of a non‐intrusive Raman spectroscopic method compared with HPLC for routine application to pre‐delivery analytical control of two major camptothecin analogs: irinotecan and topotecan
39. Abstract 2677: Decrease in phospho-S6 expression under MEK inhibitor (MEKi) treatment as a potential predictive biomarker of response to MEKi alone or in combination with PI3K-mTOR pathway inhibitor in pancreatic adenocarcinoma in vitro and ex vivo models
40. Decreased pS6 expression under MEK inhibitor (MEKi) correlates with response to MEKi alone or combined with PI3Ki-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models
41. Correlation of decreased pS6 expression under MEK inhibitor (MEKi) with response to MEKi alone or combined with PI3K-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models.
42. Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): Safety, efficacy, and updated translational results.
43. New applicable breakthrough of Raman spectroscopy to the verification of the analytical quality of injectable solutions of anthracyclines
44. Longer Term Follow-up on the First Patients with Severe Hemoglobinopathies Treated with Lentiglobin Gene Therapy
45. Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison
46. Pharmacokinetics/Pharmacodynamic Relationship in Busulfan Conditioning Regimen: Results from a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation
47. Mechanical performances of elastomers used in diffusers
48. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)- Globin Gene.
49. Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Simultaneous Quantification of Midostaurin (PKC412) and Its Two Major Metabolites: A Suitable Tool for the Monitoring of the Drug in Patients Suffering From Advanced Systemic Mastocytosis
50. Evaluation of circadian variation of blood pressure by ambulatory blood pressure monitoring in an elderly diabetic population with or without orthostatic hypotension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.